Beyond BRCA the Future is Now
|
|
- Gwendolyn McKinney
- 8 years ago
- Views:
Transcription
1 Beyond BRCA the Future is Now Richard P. Frieder, MD Medical Director, Intelegene Assistant Clinical Professor Department of Obstetrics and Gynecology David Geffen School of Medicine, UCLA University of California Los Angeles, California
2 Who Am I? A Gynecologist. Why am I here? To help you help your patients. To save lives. Personalized Medicine and Genomics... a form of medicine that uses information about a person s genes, proteins, and environment to prevent, diagnose and treat disease National Cancer Institute (NCI), 2011
3 Hereditary Cancer Risk Assessment (HCRA) Obstetricians and gynecologists play an important role in the identification and management of women with hereditary breast and ovarian cancer syndrome. Evaluating a patient s risk for hereditary breast and ovarian cancer (HBOC) syndrome should be a routine part of obstetric and gynecologic practice. American College of Obstetricians and Gynecologists Practice Bulletin 103 (2009). Hereditary Cancer Risk Assessment (HCRA) Testing for inherited predisposition is well established for patients at hereditary cancer risk... to inform clinical decision making and cancer prevention. It is the role of health care providers to offer genetic testing. American Society of Clinical Oncology, 2013
4 Hereditary Cancer Panel Testing Then & Now A new paradigm of clinical genetic testing for inherited cancer risk Old model: Gene focused Single or small panel of highly penetrant genes Sequential analysis of specific genes/syndromes DDX based on personal and family history New model: Cancer focused Large panel of highly and moderately penetrant genes Simultaneous analysis of multiple genes/syndrome DDX based on personal and family history Before and After Panel Testing Before Panel Testing After Panel Testing Hereditary Hereditary Sporadic Sporadic
5 Evolution 102: What I ve seen <10,000 tests run <500 US testers Most testing by GCs Most testing in academics Most mutations found by GCs VUS rate (BRCA) 13% Referral model accepted Point-of-care model proposed 2014 >1.2 million tests run >60,000 US testers Most testing by Docs/NPs Most testing in community Most mutations found by clinicians VUS rate (BRCA) <1.5% Referral model fails Point-of-care model superior BRCA=breast cancer gene; VUS=variant of uncertain significance. Evolution 102: I ve seen more 1998 M&M studies in progress Cost effectiveness speculated Clinician awareness low Public awareness low Insurance coverage poor Society guidelines none Physician liability low Practice revenue unknown 2014 M&M benefits confirmed Cost effectiveness confirmed Clinician awareness high Public awareness high Insurance coverage good Society guidelines ubiquitous Physician liability high Practice revenue positive
6 Evolution 103: Models of Care Goals Traditional GC Model* 1) To help patients to understand and adapt to medical, psychological, and familial implications of genetic contributions to disease 2) To educate patients about inheritance, testing, management, prevention, resources, and research 3) To counsel patients, and to promote informed choices and adaptation to risk or condition Point-of-Care Medical Model 1) To prevent, diagnose, and treat disease 2) To ease suffering, promote health, and lengthen life 3) To advise and guide decisionmaking with patients through informed consent *National Society of Genetic Counselors Bulletin, What Are Multigene Next Generation Sequencing Panels? Rapid simultaneous analysis of multiple genes Lower cost than sequential analysis Shorter time to diagnosis
7 What are Multigene Next Generation Sequencing Panels? Covers complex cancer pedigrees that cross syndromes Increases identification of causative mutations Expands spectra of cancers associated with candidate genes Up to 30% syndromic overlap between HBOC and Lynch Hereditary Cancer Panel Testing What is available TODAY! 8 to 40 gene panels of high/moderate penetrance genes Covers 8 major cancer sites and inherited cancers: Breast, Ovary, Colon, Gastric, Endometrium, Pancreas, Melanoma, Prostate (+others) Clinically actionable mutations (>2x RR or >5% AR) Captures up to 50% more mutation carriers than single-gene or syndrome-focused testing Greater clinical utility than current syndrome tests AR=absolute risk; RR=relative risk.
8 Who is the target population? Affected patients meeting NCCN test criteria Unaffected patients with family history, meeting NCCN test criteria Personal or family history of multiple cancers not fitting classic syndrome Previous uninformative (negative) test results NCCN=National Comprehensive Cancer Network. What genes are tested? Familiar BRCA1 BRCA2 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH (MYH) CDKN2A (P16) HBOC LYNCH GI Polyposis Melanoma/Pancreatic
9 What genes are tested? Familiar New BRCA1 BRCA2 HBOC CDK4 TP53 PALB2 RAD51C MLH1 PTEN RAD51D MSH2 MSH6 PMS2 LYNCH STK11 CDH1 BMPR1A BRIP1 BARD1 NBN EPCAM SMAD4 CHEK2 APC MUTYH (MYH) CDKN2A (P16) GI Polyposis Melanoma/Pancreatic ATM CHEK1 GEN1 MRE11A RAD50 XRCC2 N Engl J Med, Foulkes WD, Inherited susceptibility to common cancers, vol. 359, Copyright Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
10 BST OVY CRC UT MEL PAN GAS PROS OTHER BRCA1,2 X X X X X X X X X X X X MLH 1, MSH6 MSH2 X X X X X X X X X X X X PMS2, EPCAM APC X X X X MUTYH X X CDKN2A X X TP53 X X X X X X X X X PTEN X X X X STK11 X X X X X X CDH1 X X X BMPR1A X X X X SMAD4 X X X X PALB2 X X X CHEK2 X X X ATM X X NBN X X BARD1 X BRIP1 X X RAD51C X X RAD 51D X Just because it comes in a box, doesn t mean it s pizza. Just because it comes in a panel, doesn t mean it s good
11 Not all panel tests and labs are equally accurate. Not all results are equally reliable. One wrong result affects thousands of patients. CLIA certification does not assure quality. CLIA=Clinical Laboratory Improvement Amendments. Data to Demand From Any Genetic Laboratory That We May Use 1. Published results of validation studies with numbers of patients and diagnostic accuracy 2. Published results of VUS rates for each gene in panel 3. Databases and methods used to assign variant classification 4. Periodic review schedule and notification for VUS reassignment 5. GC review confirm optimal test was ordered 6. Turn-around time 7. Genetic education and interpretive resources to physicians 8. Office assistance for process integration 9. Actual out-of-pocket cost to the patient 10. Retail total cost of test
12 So What Do We Need to Know? Diving Deeper Expanding Differentials, Individualizing Management Shari Goldman Snow, MD Assistant Professor Northwestern University Chicago, Illinois
13 Clinical Dilemma Expand Testing From Single Syndrome Many patients have personal and family history associated with multiple syndromes 6.9% of patients appropriate for HBOC testing also meet Lynch criteria 30% of patients appropriate for Lynch testing also meet HBOC criteria Saam J et al. Overlap between Lynch syndrome and hereditary breast and ovarian cancer syndrome among family histories in patients tested for hereditary cancer syndromes. The Collaborative Group of the Americas on Inherited Colorectal Cancer. Poster 2013.
14 Case 1: Jennifer 32-year-old healthy female Mother diagnosed with ovarian cancer at age 48 Maternal grandfather diagnosed with colon cancer at age 63 Presently plans to start mammography at age 40 and colonoscopy at age 50 Which risks does Jennifer have? Hereditary Breast & Ovarian Cancer (HBOC) Lynch Syndrome Domchek SM et al. Breast Cancer Res Treat. 2010;119(2): Vasen HF et al. Gastroenterology. 1996;110(4)
15 Case 2: Carol 56-year-old diagnosed with breast cancer at age 44 Father diagnosed with pancreatic cancer at age 62 Paternal aunt diagnosed with colon cancer at age 68 Presently has a mammogram yearly and colonoscopy every 10 years What If Carol s Test Reveals.. BRCA Breast, Ovarian, Pancreatic Add: MRI, Mastectomy, BSO, Imaging PTEN Breast, Colon, Uterine Add: MRI, Mastectomy, Colonoscopies, Hysterectomy MLH1 Negative Colon, Uterine, Ovarian, Pancreatic, Gastric Small increases over general population Add: Colonoscopies, Colectomy, Hysterectomy/BSO, Endoscopy, Imaging Continue present management BSO=bilateral salpingo-oophorectomy; MRI=magnetic resonance imaging.
16 Expand to Panel Screening Case 3: Julie 46-year-old healthy female, G3P3 Mother diagnosed with Stage IV colon cancer at age 58 Paternal grandmother diagnosed with colon cancer at age 60 and with ovarian cancer at age 80 Colonoscopy every 3 years from age 40 Mammogram yearly from age 40
17 Panel Testing Results: BRCA + BEFORE: Screening Mammogram AFTER: Add MRI, Considering Mastectomy BEFORE: Annual Pelvic Examinations AFTER: LSC BSO BEFORE: Colonoscopy every 3 years AFTER: Colonoscopy every 5 years, based on family history, negative genetic results for colon cancer LSC=laparoscopic. Expand the Differential, Individualize Management
18 Potential Patient Management Pitfalls MARRA S. FRANCIS, MD, FACOG WOMEN S HEALTH CONSULTANTS SAN ANTONIO, TEXAS 10:15 AM: M.J., Return OB Visit M.J. is a 37yo G3P2, uncomplicated pregnancy, currently 28 weeks gestation Expresses her desire to have a postpartum BTL Normal body habitus Chart notation that, per the patient, vasectomy was discussed and declined by her husband BTL=bilateral tubal ligation.
19 Labor and Delivery: 11 weeks later M.J. has a successful NSVD on Monday, epidural placed during labor Tuesday, M.J. is taken to the OR suite and a mini-lap via umbilical incision is made Postpartum BTL is successfully performed NSVD=normal spontaneous vaginal delivery. Four Years Later: M.J., 2:30 PM Gyn Problem bloating M.J. has been experiencing bloating and weight gain for the past month Examination reveals slight abdominal fluid wave and bilateral pelvic masses
20 Diagnosis Ultrasound confirms bilateral cystic/solid masses consistent with malignancy CT Scan reveals omental caking and a liver lesion consistent with metastatic disease CA125 = 314 U/mL (normal <35 U/mL) Stage IIIC Ovarian Carcinoma Closer Examination of Cancer Family History Paternal Grandmother: Ovarian cancer diagnosed at age 47; deceased age 49 Paternal Aunt: Colon cancer diagnosed at age 56; deceased age 60 Father: Colon cancer diagnosed at age 49; deceased age 52
21 Flash Back to 4 Years Prior HAD a Cancer Family History form designed to identify individuals at risk for Hereditary Cancer Syndromes been done at the first OB visit, M.J. would have been found to be at risk for both HBOC and Lynch Syndrome Single Syndrome gene testing for BRCA and Lynch would have been negative Panel Testing Results M.J. is found to be a carrier of STK11 (Peutz-Jeghers Syndrome) gene mutation
22 STK11 (Peutz-Jeghers Syndrome) Regulates the tumor suppressor enzyme serine/threonine kinase 11 STK11 is also involved in cellular apoptosis Clinical Significance Noncancerous hamartomatous polyps of the GI tract Cancer of: GI Tract, Pancreas, Cervix, Ovary, Breast, Skin (Melanoma) Better Medical/Surgical Management for M.J. Standard of Care for her desired sterilization would have been a recommendation for hysterectomy/ bilateral salpingo-oopherectomy sometime after 6 weeks post partum Increased colon cancer surveillance Increased skin surveillance for melanoma Increased breast cancer surveillance No guidelines on pancreatic cancer surveillance at this time
23 1:45 PM: T.R., Breast Problem T.R. is a 43yo G2P2, BMI 25, Breast Size 38DD Referred by plastic surgeon for preoperative breast examination and mammogram for breast reduction surgery Pap smear is up to date Prior mammogram at age 41, normal BMI=body mass index. 1:45 PM: T.R., Breast Problem (continued) Normal breast examination noted Screening mammogram done, BI-RADS 1 Three weeks later, T.R. has an uncomplicated bilateral breast reduction with lift 6-month follow-up mammogram done to have a new baseline Routine breast screening continued BI-RADS 1=Breast Imaging Reporting and Data System [category 1].
24 Three Years Later: 8:30 AM, T.R. Urgent Visit breast mass T.R. noticed a hard lump at the edge of her mastopexy scar Had previously contacted the plastic surgeon, who recommended massage and topical scar cream application; no change in 1 month Last mammogram 9 months ago, BI-RADS 3, increased scar tissue bilaterally noted and close interval follow-up recommended Patient had to cancel her 6-month follow-up for a family emergency and forgot to reschedule T.R. Examination Solid mass palpated at lateral edge of mastopexy scar Urgent diagnostic mammogram with ultrasound and biopsy, as needed, ordered
25 Diagnosis Mammogram reveals solid, spiculated mass enlarged from previous scan, and enlarged lymph nodes in axillary region Biopsy reveals high-grade invasive ductal carcinoma T.R. diagnosed with Stage IIB IDCA of the breast IDCA=infiltrating ductal carcinoma. Closer Examination of Cancer Family History Maternal Grandmother: Pancreatic cancer diagnosed at age 60; deceased age 61 Maternal Aunt: Breast cancer diagnosed at age 59; deceased age 66 Maternal First Cousin: Breast cancer diagnosed at age 46; living Mother: Pancreatic cancer recently diagnosed at age 67; undergoing treatment
26 Flash Back to 3 Years Prior HAD a Cancer Family History form designed to identify individuals at risk for hereditary cancer syndromes been done at the preoperative breast visit, T.R. would have been found to be at risk for HBOC Single Syndrome gene testing for BRCA would have been negative Panel Testing Results T.R. is found to be a carrier of PalB2 mutation PalB2=partner and localizer of BRCA2.
27 PalB2 (FANC: Fanconi Anemia, Complementation Groups) PalB2 protein works with BRCA2 gene s tumor suppressor function Clinical Significance Two abnormal copies of PalB2 result in Fanconi Anemia, increases childhood cancer rates Wilms Tumor and medulloblastoma One abnormal copy of PalB2 increases adult cancer rates Breast and pancreatic Better Medical/Surgical Management Standard of care would have been to offer bilateral risk reduction prophylactic mastectomies OR increased breast surveillance No guidelines on pancreatic cancer surveillance at this time
28 HOW TO INCORPORATE HEREDITARY CANCER TESTING INTO A BUSY PRACTICE Burton S. Brodsky, MD Associate Professor Wayne State University School of Medicine Detroit, Michigan ACOG Recommends the Use of Protocols and Tracking Systems To enhance quality of care and patient safety: ACOG=American College of Obstetricians and Gynecologists. 1. Committee on Patient Safety and Quality Improvement, American College of Obstetricians and Gynecologists. Committee Opinion No. 546: Tracking and reminder systems. Obstet Gynecol. 2012;120(6): ACOG Committee on Patient Safety and Quality Improvement. ACOG Committee Opinion No. 526: Standardization of practice to improve outcomes. Obstet Gynecol. 2012;119(5):
29 Do You Need a Cancer Family History for All Patients? ACOG Committee Opinion, No. 478, March 2011 Family history plays a very important role in assessing the risk of inherited medical conditions and single gene disorders It is recommended that all women receive a family history evaluation as a screening tool for inherited risk. Family history information should be reviewed and updated regularly, especially when there are significant changes to family history SCREEN WRITTEN FHQ Use written cancer FHQ with all patients every visit Remind patients to be complete and accurate when filling out FHQ, including paternal side ACOG recommends that all women receive a family history evaluation as screening for inherited risk; this should be updated regularly. ACOG Committee Opinion 478, March 2011 FHQ=Family History Questionnaire.
30 Risk Assessment for Lynch Syndrome and Hereditary Breast and Ovarian Cancer Syndrome Patient Name: Physician: Date of Birth: Today s Date: This is a screening tool for cancers that run in families. Please consider these family members when completing the form: Mother/Father/Sister/Brother/Children = 1st Degree Relatives Aunt/Uncle/Grandparent/Niece/Nephew = 2nd Degree Relatives Cousin/Great Grandparent = 3rd Degree Relatives Have you or any of your relatives been tested for hereditary cancer (BRCA/Colaris) in the past? YES NO COLON AND UTERINE CANCER (Lynch Syndrome/Colaris) EXAMPLE: Two or more relatives with a Lynch syndrome Y N cancer; one under age 50 Have YOU been diagnosed with uterine (endometrial) or Y N colorectal cancer before age 50 TWO or more relatives on the same side of the family w/ any of the following, one diagnosed before 50 (please circle): Y N colon, uterine/endometrial, ovarian, stomach, small bowel, brain, kidney/urinary tract, ureter and renal pelvis THREE or more relatives on the same side of the family w/ any of the following diagnosed at any age (please circle): Y N colon, uterine/endometrial, ovarian, stomach, small bowel, brain, kidney/urinary tract, ureter and renal pelvis Y N Family member has a known Lynch syndrome mutation SELF YOUR RELATIONSHIP TO FAMILY MEMBER w/ CANCER MOTHER S SIDE FATHER S SIDE Aunt-colon Sister-uterine AGE AT DIAGNOSIS 47 yrs 60 yrs YOUR RELATIONSHIP TO FAMILY BREAST AND OVARIAN CANCER (HBOC/BRACAnalysis) SELF MEMBER w/ CANCER MOTHER S SIDE FATHER S SIDE Breast cancer at age 45 or younger Y N (in self, first or second degree family members) Ovarian cancer at any age Y N (in self, first or second degree family members) TWO relatives on the same side of the family with breast Y N cancer with one under the age of 50 THREE relatives on the same side of the family with breast Y N cancer at any age Multiple breast cancers in the same person (in the same Y N breast or in both breasts) Y N Male breast cancer at any age Ashkenazi Jewish ancestry with breast, ovarian or pancreatic Y N cancer in the same person or on the same side of the family Pancreatic cancer with breast or ovarian cancer in the same Y N person or on the same side of the family Triple Negative breast cancer under age 60 Y N (ER, PR and Her2 negative receptor status) Y N A family member with a known BRCA mutation Is there any other cancer in you or any family members not listed above (provide site, relationship and age): AGE AT DIAGNOSIS Patient s signature: Date: FOR OFFICE USE ONLY Patient is appropriate for further risk assessment and/or genetic testing Information given to patient to review Follow-up appointment scheduled on Patient offered genetic testing: Accepted OR Declined HCP Signature: a EVALUATE APPLY CRITERIA Review all FHQs and document Use consistent testing criteria and evaluation methods
31 DIAGNOSE APPLY CRITERIA FOLLOW UP Test appropriate patients Use follow up protocol for all patients whether tested or not Document follow up appropriately MANAGE FOLLOW UP Document results and management Communication plan for patients and referring providers PLAN Manage patients according to individualized risk Document individualized medical management plan Involve other providers as appropriate
32 Active Use of Cancer Family History Helps to Ensure You Are Making Optimal Recommendations ACOG, 1 USPSTF, 2 and NCCN 3 guidelines exist for Hereditary Cancer Risk Assessment Optimal medical recommendations for all patient visit types: Well woman visit Problem visit OB visit May increase patient safety and quality of care USPSTF=US Preventive Services Task Force. 1. American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009; 113(4): U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143(5): National Comprehensive Cancer Network.
Hereditary Breast Cancer Panels. High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel
P A T I E N T G U I D E Hereditary Breast Cancer Panels High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel B a y l o r M i r a c a G e n e t i c s L a b o r a t
More informationOvarian Cancer Genetic Testing: Why, When, How?
Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine
More informationThe Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine
The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary
More informationCommon Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
More informationGenetics and Breast Cancer. Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service
Genetics and Breast Cancer Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service Overview Background/Our Team What is the difference between sporadic/familial cancer? How
More informationHereditary Breast Cancer Testing. Diagnostic
Hereditary Cancer Testing Diagnostic New solutions for hereditary breast cancer. Identifying and understanding the genetic contribution to breast cancer allows for individualized disease management and
More informationAdvice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals DECEMBER 2010
Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals DECEMBER 2010 This guide has three parts: 1. Information for health professionals 2. Tables
More informationGENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP
GENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP WHO IS AT HIGH RISK OF HEREDITARY CANCER? Hereditary Cancer accounts for a small proportion of all cancer or approximately 5-10% THE DEVELOPMENT
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationSurgical History (Please provide Month/Year for all that apply):
DATE: Name: First MI Last Maiden Date of Birth: Reason for Visit: Primary Care Provider: Personal Medical History (PLEASE CHECK ALL THAT APPLY): Diabetes, Type 1 Seizures High Blood Pressure Migraine/Headaches
More informationTest Information Sheet
Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: High/Moderate Risk Panel Sequence
More informationHereditary Breast Cancer. Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center
Hereditary Breast Cancer Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center Outline Background Assessing risk of patient Syndromes BRCA 1,2 Li Fraumeni Cowden Hereditary
More information6/10/2015. Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond. Hereditary Cancers. BRCA1 and BRCA2 Review
Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond Arturo Anguiano MD, FACMG International Medical Director, Medical Affairs Vice Chairman, Genetics; Medical Director,
More informationHereditary Cancer Risk Assessment: Indicators of Hereditary and Familial Risk
Hereditary Cancer Risk Assessment: Indicators of Hereditary and Familial Risk Karen Copeland Certified Genetic Counselor Director International Medical Affairs Myriad Genetics GmbH Impact of Hereditary
More informationNOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES
NOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES GP Referrals All GP referrals for asymptomatic women with a family history of breast and/or
More informationPatient Support Guide
Patient Support Guide to genetic testing for hereditary breast and ovarian cancer syndrome Testing for BRCA1 and BRCA2 is available from Quest Diagnostics. Quest Diagnostics Patient Support Guide to Genetic
More informationHereditary Breast and Ovarian Cancer (HBOC)
Oxford University Hospitals NHS Trust Oxford Regional Genetic Department Hereditary Breast and Ovarian Cancer (HBOC) Information for women with an increased lifetime risk of breast and ovarian cancer What
More informationBRCA Genes and Inherited Breast and Ovarian Cancer. Patient information leaflet
BRCA Genes and Inherited Breast and Ovarian Cancer Patient information leaflet This booklet has been written for people who have a personal or family history of breast and/or ovarian cancer that could
More informationScreenWise. Breast, Cervical, and Hereditary Cancer Screenings OCTOBER 28, 2015
ScreenWise Breast, Cervical, and Hereditary Cancer Screenings OCTOBER 28, 2015 ScreenWise Three programs working together to bring quality screening services to Oregon residents Why we all do this work
More informationpatient guide BRCA1 and BRCA2 Genetic Testing for Hereditary Breast and Ovarian Cancer
patient guide BRCA1 and BRCA2 Genetic Testing for Hereditary Breast and Ovarian Cancer What is hereditary cancer? Cancer affects many people in the U.S.: breast cancer affects 1 in 8 women and ovarian
More informationUnderstanding Lynch Syndrome
ESSENTIALS Lynch Syndrome Understanding Lynch Syndrome Certain cancers can run in families. Sometimes this happens because of harmful changes (called mutations) in our genes that are passed from one generation
More informationOregon Survey Instrument
Oregon Survey Instrument Cancer Genetic Insurance Questions for Insurers Q1a. Do you have written policies on your coverage of cancer genetic testing, counseling, and follow-up procedures for breast and
More informationGenetic Testing for Familial Adenomatous Polyposis and MYH-Associated Polyposis (Lynch Syndrome)
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationRisk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth
Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes Dr. med. Henrik Csaba Horváth Why is risk stratification for colorectal cancer (CRC)
More informationUnderstanding Your Risk of Ovarian Cancer
Understanding Your Risk of Ovarian Cancer A WOMAN S GUIDE This brochure is made possible through partnership support from Project Hope for Ovarian Cancer Research and Education. Project HOPE FOR OVARIAN
More informationScreening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group
Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection
More informationCancer Screening and Early Detection Guidelines
Cancer Screening and Early Detection Guidelines Guillermo Tortolero Luna, MD, PhD Director Cancer Control and Population Sciences Program University of Puerto Rico Comprehensive Cancer Center ASPPR Clinical
More informationGynecologic Cancer in Women with Lynch Syndrome
Gynecologic Cancer in Women with Lynch Syndrome Sarah E. Ferguson, MD FRCSC Division of Gynecologic Oncology, Princess Margaret Hospital, University of Toronto June 11, 2013 Objective 1. To review the
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES BRCA GENETIC TESTING The purpose of this document is to provide guidance to providers enrolled in the Connecticut Medical Assistance Program (CMAP) on the requirements for
More informationif your family has a history
if your family has a history OF CANCER. put it to the test. Learn about your risk for hereditary and ovarian and how you can reduce it. do you have a family history of Breast or Ovarian Cancer? what does
More informationFrequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
More informationBRCA1 & BRCA2 GeneHealth UK
BRCA1 & BRCA2 GeneHealth UK BRCA1 & BRCA2 What is hereditary breast cancer? Cancer is unfortunately very common, with 1 in 3 people developing cancer at some point in their lifetime. Breast cancer occurs
More informationThe Department of Vermont Health Access Medical Policy
State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 [Phone] 802-879-5903 Williston, VT 05495-2807 [Fax] 802-879-5963 www.dvha.vermont.gov Agency of Human Services The Department
More informationBRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide
BRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide What is Hereditary? Breast cancer is the most common cancer in women in the U.S. (it affects about 1 in 8 women). Ovarian
More informationBreast Cancer s Link to Ovarian Cancer: It s in Your Genes. foundationforwomenscancer.org
Breast Cancer s Link to Ovarian Cancer: It s in Your Genes foundationforwomenscancer.org There are now more than 2.6 million women in America who have been diagnosed with breast cancer. A very small fraction
More informationKate O Hanlan, M. D. F. A. C. O. G., F. A. C. S.
Kate O Hanlan, M. D. F. A. C. O. G., F. A. C. S. Gynecologic Oncology, Surgery and Endoscopy 4370 Alpine Road Portola Valley, CA 94028-7523 Phone: (650)-851-6669 FAX: (650) 851-9747 Regarding Ovarian Cancer,
More informationFamilial Breast Cancer Referrals and Risk Management
Familial Breast Cancer Referrals and Risk Management Presented by: Helen Mountain Genetic Counsellor Genetic Services of WA Perth (KEMH and PMH) Joondalup Rockingham Bunbury Geraldton Kalgoorlie Albany
More informationPrevention GENEration. The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
הסיכוי שבסיכון PREVENTION GENERATION Prevention GENEration The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC) We thank Prof. Ephrat Levy-Lahad Director, Medical
More informationA Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services. Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD
A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD Importance of Family History Increasing awareness of
More informationScreening guidelines tool
Screening guidelines tool Disclaimer: This material is intended as a general summary of screening and management recommendations; it is not intended to be comprehensive. Colorectal cancer (CRC) screening
More informationTest Information Sheet
Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: Breast/Ovarian Cancer Panel Sequence
More informationBreast and Ovarian Cancer
Breast and Ovarian Cancer Hereditary Breast and Ovarian Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS Hereditary Breast and Ovarian Cancer Panel
More informationBreast Cancer. CSC Cancer Experience Registry Member, breast cancer
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
More informationColon Cancer Syndromes. Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service
Colon Cancer Syndromes Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service Background: Etiology of Colorectal Cancer (CRC) Sporadic:
More informationBRCA1 and BRCA2. BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS
BRCA1 and BRCA2 BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS BRCA1 and BRCA2 Breast cancer is the most common cancer in women, diagnosed in
More informationAre You at Risk for Ovarian Cancer?
Are You at Risk for Ovarian Cancer? A Woman s Guide Read this brochure to learn more about ovarian cancer symptoms, risk factors and what you can do to reduce your risk. ALL WOMEN HAVE SOME RISK OF OVARIAN
More informationINTERVENTIONS BREAST CANCER GENETICS YOUNG BREAST CANCER SURVIVORS
INTERVENTIONS BREAST CANCER GENETICS YOUNG BREAST CANCER SURVIVORS AND THEIR AT-RISK RELATIVES Maria C. Katapodi, PhD, RN, FAAN Professor of Nursing Faculty of Medicine, University of Basel, Switzerland
More informationHereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center
Hereditary Multifocal Breast Cancer Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center CASE STUDY 30 year old Ashkenazi Jewish woman Nulliparous Felt
More informationIllinois Insurance Facts Illinois Department of Insurance
Illinois Insurance Facts Illinois Department of Insurance Women s Health Care Issues Revised August 2012 Note: This information was developed to provide consumers with general information and guidance
More informationName of Policy: Genetic Testing for Hereditary Breast and/or Ovarian Cancer
Name of Policy: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Policy #: 513 Latest Review Date: January 2014 Category: Laboratory Policy Grade: B Background/Definitions: As a general rule,
More informationCancer Genetic Counseling
Cancer Genetic Counseling Guest Expert: Ellen, MS Director of the Yale Cancer Center Cancer Genetic Counseling Program www.wnpr.org www.yalecancercenter.org I am Bruce Barber and this is Yale Cancer Center
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS. POLICY NUMBER: 2.02.06 CATEGORY: Laboratory Test
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR, 10/15/15 PAGE: 1 OF: 12 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationBreast Health Program
Breast Health Program Working together, for your health. Breast Health Program The Breast Health Program at The University of Arizona Cancer Center offers patients a personalized approach to breast cancer,
More informationGENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110
GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110 COVERAGE: Pre- and post-genetic test counseling may be eligible for coverage in addition to the genetic
More informationHereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013
Hereditary Ovarian cancer: BRCA1 and BRCA2 Karen H. Lu MD September 22, 2013 Outline Hereditary Breast and Ovarian Cancer (HBOC) BRCA1/2 genes How to identify What it means to you What it means to your
More informationOffice of Population Health Genomics
Office of Population Health Genomics Policy: Protocol for the management of female BRCA mutation carriers in Western Australia Purpose: Best Practice guidelines for the management of female BRCA mutation
More informationFollow-Up Care for Breast Cancer
A Patient s Guide Follow-Up Care for Breast Cancer Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is a nonprofit organization which represents
More informationOvarian Cancer. What is cancer?
What is cancer? Ovarian Cancer The body is made up of trillions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly way. During the early years of a person's life,
More informationGenetic Counseling and Testing: Cancer Genetics
KAISER PERMANENTE HAWAII CLINICAL PRACTICE GUIDELINE Genetic Counseling and Testing: Cancer Genetics QUALITY COMMITTEE ADOPTION DATE: October 2015 LAST REVIEW DATE: September 2015 NEXT SCHEDULED REVIEW
More informationBRCA in Men. Mary B. Daly,M.D.,Ph.D. June 25, 2010
BRCA in Men Mary B. Daly,M.D.,Ph.D. June 25, 2010 BRCA in Men Inheritance patterns of BRCA1/2 Cancer Risks for men with BRCA1/2 mutations Risk management recommendations for men with BRCA1/2 mutations
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: May 2015 Policy No: 02 Effective Date:
More informationgenetic &testing * VC: Explain more about genetic counseling for pancreatic cancer. What s involved?
volume III/winter 2009 Harold Frucht, M.D. genetic counseling &testing * Virginia Cravotta (VC): Please define genetics and genetic testing, and explain how testing might be useful to individuals concerned
More informationHEREDITARY BRCA1. Faulty gene INFORMATION LEAFLET. How Do I Reduce My Risk?
HEREDITARY BREAST CANCER BRCA1 Faulty gene INFORMATION LEAFLET How Do I Reduce My Risk? Page 1 CONTENTS Part A 1 What is BRCA1 2 How does BRCA1 affect a person s risk of cancer? 3Testing for BRCA1 4Benefits
More informationClinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Frequency of visit as recommended by PCP
SCREENING EXAMINATION & COUNSELING UPMC Health Plan Clinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Annually Physical Exam and Counseling 1 Blood Pressure 2 At each visit. At least
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationThe Hereditary Colorectal Cancer Website has been sponsored by the Robert Rauschenberg Foundation
Introduction The Hereditary Colorectal Cancer Website has been sponsored by the Robert Rauschenberg Foundation Hereditary nonpolyposis colorectal cancer (HNPCC) syndrome was first described over 100 years
More informationBreast Cancer Screening
Breast Cancer Screening Summary of the Clinical Practice Guideline September 2013 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate
More informationBreast cancer in families. This booklet explains what a family history of breast cancer is, and what this may mean for you or your family.
Breast cancer in families This booklet explains what a family history of breast cancer is, and what this may mean for you or your family. Worried Lorem about ipsum breast dolore cancer estes Contents
More informationBreast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.
Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are
More informationGenetic/Familial High-Risk Assessment: Breast and Ovarian
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Genetic/Familial High-Risk Assessment: Version 2.2015 NCCN.org Continue Version 2.2015, 06/25/15 National Comprehensive Cancer Network,
More informationBreast Cancer Follow-Up
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Follow-Up Breast Cancer Follow-Up Version 2002: Thomssen / Scharl Version 2003 2009: Bauerfeind / Bischoff /
More informationPre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013
Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013 Objectives After completion of this presentation, the participant will be able to: Explain the current
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationOvarian Cancer. Understanding your diagnosis
Ovarian Cancer Understanding your diagnosis Ovarian Cancer Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed by the large amount
More informationACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
PRACTICE GUIDELINES nature publishing group 223 CME ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sapna Sy nga l, MD, M PH, FAC G 1, 2, 3, R and
More informationAetna Life Insurance Company
Aetna Life Insurance Company Hartford, Connecticut 06156 Amendment Policyholder: Group Policy No.: Effective Date: UNIVERSITY OF PENNSYLVANIA POSTDOCTORAL INSURANCE PLAN GP-861472 This Amendment is effective
More informationCervical Cancer Screening and Management Guidelines: Changing Again, Huh?
Cervical Cancer Screening and Management Guidelines: Changing Again, Huh? Summary of 2013 recommendations from ASC (American Cancer Society), ASCCP (American Society for Colposcopy and Cervical Pathology),
More informationUnderstanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE
Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Introduction This guide is designed to help you clarify and understand the decisions that need to be made about your care for the
More informationDraft Benefit Coverage Standard for Genetic Testing Recommendations
Draft Benefit Coverage Standard for Genetic Testing Recommendations Colorado Medicaid Benefits Collaborative Meeting: February 12, 2015 Authored by: Devki S. Saraiya, MS, CGC, Licensed Genetic Counselor
More informationNumber. Source: Vital Records, M CDPH
Epidemiology of Cancer in Department of Public Health Revised April 212 Introduction The general public is very concerned about cancer in the community. Many residents believe that cancer rates are high
More informationGuide to Understanding Breast Cancer
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
More informationExamples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.
CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests
More informationBreast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA
Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for
More informationBREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt
Ali A. Kader, S. (2010). Breast cancer awareness for women and men. UCQ Nursing Journal of Academic Writing, Winter 2010, 70 76. BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader Two years
More informationGenetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS -
Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS - January 2005 SCIENTIFIC BACKGROUND Breast cancer is considered to be one of the most prevalent cancer in women. The overall
More informationScreening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine Practice Policy Statement
ATTENTION This Policy was reaffirmed by the ACPM Board of Regents on 1/31/2005 and is effective through 1/31/2010. Screening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine
More informationParker Adventist Hospital Genetic Counseling Family History Questionnaire
PATIENT NAME: To be completed by Questionnaire received: Genetic Counseling Clinic: Parker Adventist Hospital Genetic Counseling History Questionnaire Appointment: You have been referred to Genetic Counseling
More informationScreening Guidelines for Malignancy Michael T. Milano, MD PhD
Screening Guidelines for Malignancy Michael T. Milano, MD PhD Department of Radiation Oncology University of Rochester School of Medicine and Dentistry Identify patient population to be screened General
More informationEvaluation and Management of the Breast Mass. Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003
Evaluation and Management of the Breast Mass Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003 Common Presentations of Breast Disease Breast Mass Abnormal
More informationBreast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
More informationGet the Facts About Gynecologic Cancer
Get the Facts About Gynecologic Cancer Cervical Ovarian Uterine Vaginal Vulvar Get the Facts About Gynecologic Cancer U.S. Department of Health and Human Services Centers for Disease Control and Prevention
More informationWhat s In Your Genes: How changes in the BRCA1/BRCA2 genes
ESSENTIALS BRCA1/BRCA2 Mutations What s In Your Genes: How changes in the BRCA1/BRCA2 genes might affect you and your family Our genes contain the codes for producing the proteins that are the building
More informationOverview of testing for Lynch syndrome/hnpcc
Overview of testing for Lynch syndrome/hnpcc This overview provides detailed information about interpreting MSI/IHC testing and genetic testing for Lynch syndrome/hnpcc. It is intended to be a reference
More informationNational Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28)
National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28) Tracking Information Publication Number Manual Section Number 100-3 190.28 Manual Section Title Tumor Antigen by
More informationGenetic Testing for Lynch Syndrome/Colorectal Cancer and Polyposis Syndromes
Genetic Testing for Lynch Syndrome/Colorectal Cancer and Polyposis Syndromes Policy Number: Original Effective Date: MM.02.007 09/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO 09/01/2011
More informationGenetic Testing for Susceptibility to Breast and Ovarian Cancer (BRCA1 and BRCA 2)
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. M issouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationBenefits Collaborative Policy Statement WOMEN S HEALTH SERVICES
Page 1 uf 5 The services listed below are not inclusive of all services available to women on Medicaid, but WOMEN S HEALTH SERVICES Benefits Collaborative Policy Statement Women s health services are preventative
More informationUSPTO Roundtable Written Commentary
USPTO Roundtable Written Commentary In response to this committee s request for quantitative data, FORCE has gathered information from sources including healthcare providers, the hereditary breast and
More informationEpidemiology. Breast Cancer Screening, Diagnosis, Biology and Long-Term Follow-Up EDUCATIONAL OBJECTIVES
Cancer Treatment Centers of America Breast Cancer: Screening, Diagnosis, Biology and Long-Term Follow-Up Presented to: Atlantic Regional Osteopathic Conference Presented by: Pamela Crilley, DO Date: April
More information